Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo

Histone deacetylase (HDAC) inhibitors have received considerable attention as potential therapeutics for a variety of cancers and neurological disorders. Recent publications on a class of pimelic diphenylamide HDAC inhibitors have highlighted their promise in the treatment of the neurodegenerative d...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Beconi, Maria, Aziz, Omar, Matthews, Kim, Moumné, Lara, O’Connell, Catherine, Yates, Dawn, Clifton, Steven, Pett, Hannah, Vann, Julie, Crowley, Lynsey, Haughan, Alan F., Smith, Donna L., Woodman, Ben, Bates, Gillian P., Brookfield, Fred, Bürli, Roland W., McAllister, George, Dominguez, Celia, Munoz-Sanjuan, Ignacio, Beaumont, Vahri
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2012
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3433414/
https://ncbi.nlm.nih.gov/pubmed/22973455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044498
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items